RENAISSANCE

Renaissance Global Science & Technology Fund Performance as at March 31, 2025

Fund category

Global Equity

Investment objective

Renaissance Global Science & Technology Fund seeks to obtain longterm capital appreciation by investing in a diversified portfolio of global companies involved mainly in telecommunications, biotechnology, computer hardware and software, medical services, and other scientific and technology-based companies.

Why invest?

Active global innovation focused equity exposure

Volatility & risk analysis

Low		Medium		High			
Fund details - Class A							
Fund co	de		A	ATL1027			
Inceptio	n date		Oct	28, 1996			
Management expense ratio 2.23							
Min. inv	vestment	t		\$500			
Load str	ructure	Fr	ont End	l Charge			

Fund details - Class F


Fund code	ATL1645
Inception date	Dec 14, 2000
Management exper	nse ratio 1.06%
Min. investment	\$500
Load structure	No Sales or Redem
Total assets (\$Mil)	387.3

Annual return (%)	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	YTD
Class A		30.5	-3.3	31.1	7.3	34.8	47.0	3.2	-20.9	30.2	30.7	-5.9
Class F		32.0	-2.2	32.7	8.5	36.4	48.7	4.4	-20.0	31.8	32.2	-5.6
Trailing return	(%)	1 n	nth 3	mths	6 m	ths	1 yr	2 yrs	3 yrs	5 yrs	10 yrs	SI
Class A		-7	.2	-5.9	-1.	2	10.9	20.5	11.7	14.5	14.7	9.1
Class F		-7	.1	-5.6	-0.	6	12.2	21.9	13.0	15.9	16.1	4.2
Dist. \$	Mar	Feb	Jan	Dec	Nov	Oct	Sep	Aug	Jul	Jun	Мау	Apr
Class A	-	-	-	-	-	-	-	-	-	-	-	-
Class F	-	-	-	-	-	-	-	-	-	-	-	-

Portfolio analysis as at March 31, 2025

Investment Style: Bottom-up, growth

* Due to rounding, amounts presented herein may not add up precisely to the total.



Sector allocation	(%)
Information Technology	40.67
Health Care	40.55
Communication Services	18.78



Renaissance Global Science & Technology Fund

	Top holdings	(%)	More holdings details	Total
Investment managers	Apple Inc. Com	9.08	Total Number of Holdings	32
	NVIDIA Corp. Com	7.55		
CIBC Asset Management Inc.	Microsoft Corp. Com	7.38		
	Alphabet Inc. CI A	7.11		
	Meta Platforms Inc. CI A	5.76		
	Eli Lilly & Co. Com	5.48		
	UnitedHealth Group Inc. Com	5.32		
	Roche Holding AG Genusssch	5.08		
	Novartis AG Namen Akt	4.80		
	Thermo Fisher Scientific Inc. Com	3.93		

For more information, please contact your CIBC Asset Management representative or visit renaissanceinvestments.ca



Renaissance Global Science & Technology Fund

Renaissance Investments is offered by CIBC Asset Management Inc. The views expressed in this document are the views of CIBC Asset Management Inc. and are subject to change at any time. CIBC Asset Management Inc. does not undertake any obligation or responsibility to update such opinions. This document is provided for general informational purposes only and does not constitute financial, investment, tax, legal or accounting advice nor does it constitute an offer or solicitation to buy or sell any securities referred to. Individual circumstances and current events are critical to sound investment planning; anyone wishing to act on this document should consult with his or her advisor. All opinions and estimates expressed in this document are as of the date of publication unless otherwise indicated, and are subject to change. ®Renaissance Investments is a registered trademark of CIBC Asset Management Inc. The material and/or its contents may not be reproduced without the express written consent of CIBC Asset Management Inc.

©2025 Data Front. All Rights Reserved. The information contained herein: (1) is proprietary to Data Front and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Data Front nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. ®Renaissance Investments is offered by and is a registered trademark of CIBC Asset Management Inc. All fund performance is reported net of fees, benchmark data is reported gross of fees. This may impact a direct comparison between the fund and its benchmark.